The new tools and systems are anticipated to allow NuVax to develop three separate cancer therapeutics for the treatment of Multi Myeloma, Pancreatic Cancer and Lung Cancer.
As per the terms of the agreement, NuVax intends to leverage the four newly licensed tools and systems for selective targeting of patient tumor cells to invoke a stronger immune response in cancer patients.
RPC chairman and CEO Douglas MacLellan said they plan to leverage their experience and expertise in product development, manufacturing, regulatory approvals, and sales and marketing to fully commercialize these new therapies and technologies as rapidly as possible.